Dr. Hari Discusses the Role of MRD in Myeloma

Parameswaran Hari, MD, MRCP
Published: Tuesday, May 07, 2019



Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease (MRD) in multiple myeloma.

MRD is increasingly measurable in today’s landscape with flow cytometry and next-generation sequencing. These modalities can measure what is called MRD-0 or no disease detection. Recent frontline trials suggest that MRD can be a powerful predictor of progression-free survival and overall survival. Thus, this suggests that getting a patient to an MRD–negative state is a good surrogate for longer survival, Hari says.

Notably, he adds, MRD might be the key to curing patients with multiple myeloma since it signifies an absence of detectable disease. It is also possible that patients with MRD negativity can live the rest of their lives disease-free. There is a lot of excitement surrounding MRD in myeloma, but there are still patients who relapse even though they’ve achieved MRD negativity.
SELECTED
LANGUAGE


Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease (MRD) in multiple myeloma.

MRD is increasingly measurable in today’s landscape with flow cytometry and next-generation sequencing. These modalities can measure what is called MRD-0 or no disease detection. Recent frontline trials suggest that MRD can be a powerful predictor of progression-free survival and overall survival. Thus, this suggests that getting a patient to an MRD–negative state is a good surrogate for longer survival, Hari says.

Notably, he adds, MRD might be the key to curing patients with multiple myeloma since it signifies an absence of detectable disease. It is also possible that patients with MRD negativity can live the rest of their lives disease-free. There is a lot of excitement surrounding MRD in myeloma, but there are still patients who relapse even though they’ve achieved MRD negativity.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x